Published in Cancer Weekly, August 25th, 2009
"The primary end-point was the determination of immunogenicity of the vaccine; secondary outcomes were determination of toxicity and effect oil serum PSA. The vaccine was given Subcutaneously 7 times oil...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.